iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
GS-7977 HCV Nucleotide in Phase 3 Now
 
 
  GS-7977 Monotherapy ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 ... www.natap.org/2011/EASL/EASL_07.htm Apr 3, 2011 - PSI-938 and PSI-7977 as monotherapy and in combination were ... Of note, PSI-7977 monotherapy produced HCV RNA reductions over 7 days
 
PSI-7977: ELECTRON Interferon is not required for Sustained Virologic Response in Treatment-Naïve Patients with HCV GT2 or GT3 - (11/07/11)
 
EASL: Potent Viral Suppression With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (Nucleotide NS5B Inhibitor), +/- Ribavirin, in Treatment-Naive Patients With Chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2) - (04/19/12)
 
EASL: Once Daily GS-7977 Plus Ribavirin in HCV Genotypes 1-3: The ELECTRON Trial - (04/21/12)
 
EASL: GS-7977 + PEG/RBV in HCV Genotype 1: The ATOMIC Trial An End To Response-Guided Therapy - (04/20/12)
 
EASL: GS-7977 400 mg QD Safety and Tolerability in the Over 500 Patients Treated for at Least 12 Weeks - (04/25/12)
 
Gilead Announces Early Sustained Virologic Response Rates for ... www.natap.org/2012/EASL/EASL_21.htm Apr 19, 2012 - Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients
 
GS-7977 + Ribavirin in HCV Genotype 1 Null Responders: Results ... www.natap.org/2012/CROI/croi_07.htm GS-7977 + Ribavirin in HCV Genotype 1 Null Responders: Results from the ELECTRON Trial. Reported by Jules Levin 19th Conference on Retroviruses

figure2.gif

  
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org